Mankind Pharma Ltd
MANKINDBSE 543904PharmaceuticalsMkt cap ₹1,04,376 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹4,031 Cr
YoY +12.9%QoQ +17.1%
Net profit · Q1 FY27
₹574 Cr
YoY +29.1%QoQ +2.6%
Net margin · Q1 FY27
14.2%
+1.8 pts vs Q1 FY26
Net profit · FY26
₹1,938 Cr
YoY -3.6%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 4,031 | 3,443 | 3,567 | 3,697 | 3,570 | +12.9% |
| Other income | 45.00 | 114 | 72.75 | 91.87 | 79.88 | -43.7% |
| Total income | 4,076 | 3,557 | 3,640 | 3,789 | 3,650 | +11.7% |
| Profit before tax | 766 | 656 | 506 | 622 | 537 | +42.5% |
| Tax | 195 | 99.75 | 95.12 | 104 | 95.87 | +103.8% |
| Net profit | 574 | 559 | 414 | 520 | 445 | +29.1% |
| Net margin | 14.2% | 16.3% | 11.6% | 14.1% | 12.4% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | YoY |
|---|---|---|---|---|---|
| Revenue | 14,278 | 12,207 | 10,335 | 8,749 | +17.0% |
| Other income | 359 | 537 | 281 | 129 | -33.2% |
| Total income | 14,636 | 12,744 | 10,616 | 8,878 | +14.8% |
| Profit before tax | 2,321 | 2,504 | 2,384 | 1,659 | -7.3% |
| Tax | 395 | 510 | 458 | 362 | -22.6% |
| Net profit | 1,938 | 2,011 | 1,942 | 1,310 | -3.6% |
| Net margin | 13.6% | 16.5% | 18.8% | 15.0% |
BIC's take
We haven't covered Mankind Pharma Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:10 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.